Evidence map›Paper›PMID 31452691›Full record

ArticleTherapeutic advances in medical oncology2019

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting.

Anna Di Benedetto, Cristiana Ercolani, Laura Pizzuti, Domenico Angelucci, Domenico Sergi, Camilla Marinelli, Laura Iezzi, Francesca Sperati, Irene Terrenato, Marco Mazzotta and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Anna Di BenedettoDepartment of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Cristiana ErcolaniDepartment of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Laura PizzutiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Domenico AngelucciDivision of Pathology, 'SS. Annunziata' Hospital, Chieti, Italy.
Domenico SergiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Camilla MarinelliDivision of Pathology, 'SS. Annunziata' Hospital, Chieti, Italy.
Laura IezziDepartment of Medical and Oral Science and Biotechnologies, University G. D'Annunzio, Chieti, Italy.
Francesca SperatiBiostatistics-Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Irene TerrenatoBiostatistics-Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Marco MazzottaDepartment of Clinical and Molecular Medicine, 'Sapienza' University of Rome, Rome, Italy.
Luciano MarianiDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Enrico VizzaDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giancarlo PaolettiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Silverio TomaoMedical Oncology Unit A, Policlinico Umberto I, Rome, Italy.
Marcello Maugeri-SaccàDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Maddalena BarbaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.ORCID https://orcid.org/0000-0001-9050-2917
Nicola TinariDepartment of Medical and Oral Science and Biotechnologies, University G. D'Annunzio, Chieti, Italy.
Clara NatoliDepartment of Medical and Oral Science and Biotechnologies, University G. D'Annunzio, Chieti, Italy.
Gennaro CilibertoScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Antonino GrassadoniaDepartment of Medical and Oral Science and Biotechnologies, University G. D'Annunzio, Chieti, Italy.
Patrizia ViciDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe logic behind the outcome of endocrine therapy in breast cancer has long remained poorly understood. The prognostic role of DNA damage and repair biomarkers (DDR) was explored in postmenopausal, hormone-receptor-positive breast cancer patients treated with neoadjuvant hormone therapy (NAHT).

methodsData on 55 patients were included. The phosphorylated ataxia-teleangectasia and Rad3-related protein (pATR), phosphorylated ataxia-telangiectasia mutated (ATM) kinase, and phosphorylated H2A Histone Family Member X (γ-H2AX) were evaluated by immunohistochemistry in paired tissues collected at baseline and following NAHT. Biomarkers were considered both singularly and within signatures. Ki-67 percentage change was the primary biomarker endpoint. Classical endpoints were also considered.

resultsThe most favorable Ki-67 outcome was associated with the γ-H2AX/pATM signature (

conclusionsWe report novel evidence of the prognostic role of DDR biomarkers on important patient outcomes in postmenopausal hormone-receptor-positive breast cancer patients treated with NAHT. If confirmed in future and adequately sized trials, our results may help inform therapeutic decisions and clarify underlying biological mechanisms.

Indexed as

DNA damage and repairelderly patientshormone-receptor-positive breast cancerneoadjuvant hormone therapyprognostic biomarkers

Identifiers

PMID31452691
PMCPMC6700857

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.